Shuttle Pharma Has Received A Notice Of Allowance For Its U.S. Patent App 16/475,999 Titled “Methods & Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines & Thymidine Phosphorylase Inhibitors In Combination With Radiation”
https://patentcenter.uspto.gov/#!/applications/16475999/ifw/docs
